FDA Panel Urges Approval of Hepatitis C Drug

In an18-0 vote, an FDA advisory panel recommended approval of the drug boceprevir to treat hepatitis C.

Panel members called boceprevir, manufactured by Merck & Co., a weapon in the fight against chronic hepatitis C virus (HCV) genotype 1 infection. Chronic HCV genotype 1 infection is the most common form of hepatitis in the U.S. and also the most difficult to treat.

If approved by the FDA, boceprevir will have the brand name Victrelis.

Boceprevir is an antiviral medication called a protease inhibitor that has proven effective in adults with liver disease who have been untreated or who have failed previous therapy.  Protease inhibitors are commonly used to treat HIV infection. In the treatment of hepatitis C infection, boceprevir inhibits an enzyme, thereby suppressing replication of the hepatitis C virus.

Despite the committee’s affirmative vote, the advisors also had reservations about  boceprevir’s widespread usage.

via FDA Panel Urges Approval of Hepatitis C Drug.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s